Use of homoarginine to obtain attenuated cationic membrane lytic peptides

2021 ◽  
Vol 40 ◽  
pp. 127925
Author(s):  
Kentarou Sakamoto ◽  
Misao Akishiba ◽  
Takahiro Iwata ◽  
Jan Vincent V. Arafiles ◽  
Miki Imanishi ◽  
...  
Keyword(s):  
2020 ◽  
Vol 132 (45) ◽  
pp. 20165-20173
Author(s):  
Kentarou Sakamoto ◽  
Misao Akishiba ◽  
Takahiro Iwata ◽  
Kazuya Murata ◽  
Seiya Mizuno ◽  
...  

Molecules ◽  
2019 ◽  
Vol 24 (11) ◽  
pp. 2079 ◽  
Author(s):  
Bethany Algayer ◽  
Ann O’Brien ◽  
Aaron Momose ◽  
Dennis J. Murphy ◽  
William Procopio ◽  
...  

Delivery of macromolecular cargos such as siRNA to the cytosol after endocytosis remains a critical challenge. Numerous approaches including viruses, lipid nanoparticles, polymeric constructs, and various peptide-based approaches have yet to yield a general solution to this delivery issue. In this manuscript, we describe our efforts to design novel endosomolytic peptides that could be used to facilitate the release of cargos from a late endosomal compartment. These amphiphilic peptides, based on a chimeric influenza hemagglutinin peptide/cell-penetrating peptide (CPP) template, utilize a pH-triggering mechanism in which the peptides are protonated after acidification of the endosome, and thereby adopt an alpha-helical conformation. The helical forms of the peptides are lytically active, while the non-protonated forms are much less or non-lytically active at physiological pH. Starting from an initial lead peptide (INF7-Tat), we systematically modified the sequence of the chimeric peptides to obtain peptides with greatly enhanced lytic activity that maintain good pH selectivity in a red blood cell hemolysis assay.


2020 ◽  
Vol 142 (47) ◽  
pp. 19950-19955
Author(s):  
Stephen E. Miller ◽  
Kohei Tsuji ◽  
Rachel P.M. Abrams ◽  
Terrence R. Burke ◽  
Joel P. Schneider

Biomolecules ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1220
Author(s):  
Ashley L. Hilchie ◽  
Erin E. Gill ◽  
Melanie R. Power Coombs ◽  
Reza Falsafi ◽  
Robert E. W. Hancock ◽  
...  

Direct-acting anticancer (DAA) peptides are cytolytic peptides that show promise as novel anticancer agents. DAA peptides bind to anionic molecules that are abundant on cancer cells relative to normal healthy cells, which results in preferential killing of cancer cells. Due to the mechanism by which DAA peptides kill cancer cells, it was thought that resistance would be difficult to achieve. Here, we describe the generation and characterization of two MDA-MB-231 breast cancer cell-line variants with reduced susceptibility to pleurocidin-family and mastoparan DAA peptides. Peptide resistance correlated with deficiencies in peptide binding to cell-surface structures, suggesting that resistance was due to altered composition of the cell membrane. Peptide-resistant MDA-MB-231 cells were phenotypically distinct yet remained susceptible to chemotherapy. Surprisingly, neither of the peptide-resistant breast cancer cell lines was able to establish tumors in immune-deficient mice. Histological analysis and RNA sequencing suggested that tumorigenicity was impacted by alternations in angiogenesis and extracellular matrix composition in the peptide-resistant MDA-MB-231 variants. Collectively, these data further support the therapeutic potential of DAA peptides as adjunctive treatments for cancer.


2007 ◽  
Vol 361 (3) ◽  
pp. 712-717 ◽  
Author(s):  
Zhigang Tu ◽  
Jumin Hao ◽  
Riddhi Kharidia ◽  
Xiao G. Meng ◽  
Jun F. Liang

2008 ◽  
Vol 8 (2) ◽  
pp. 135-147 ◽  
Author(s):  
Marek Bogacki ◽  
Frederic M. Enright ◽  
William J. Todd ◽  
William Hansel

Sign in / Sign up

Export Citation Format

Share Document